Liermann, Jakob http://orcid.org/0000-0002-1445-1940
Ben-Josef, Edgar
Syed, Mustafa
Debus, Juergen
Herfarth, Klaus
Naumann, Patrick
Funding for this research was provided by:
Medizinischen Fakultät Heidelberg, Universität Heidelberg (Physician Scientist Program)
Universitätsklinikum Heidelberg
Article History
Received: 30 December 2020
Accepted: 5 July 2021
First Online: 5 August 2021
Declarations
:
: J. Debus received grants from Viewray Incorporated, The Clinical Research Institute GmbH (CRI), Accuray International Sarl, RaySearch Laboratories AB, Vision RT Limited, Merck Seono GmbH, Astellas Pharma GmbH, Astra Zeneca GmbH, Siemens Healthcare GmbH, Solution Akademie GmbH, Egomed PLC Surrey Research Park, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH&CoKG, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix SA, Accuray Incorporated, Bristol-Myer Squibb GmbH&CoKG aA, and Merck KHG aA. As chairman of HIRO (Heidelberg Institute of Radiation Oncology, Heidelberg, Germany) and a managing director of the NCT (National Center for Tumor Diseases) Heidelberg, Germany, J. Debus is responsible for collaborations with a multitude of companies and institutions. Juergen Debus is CEO of the HIT Betriebs-GmbH and a member of the board of trustees of the Physikalisch-Technische Bundesanstalt (PTB). He attended advisory board meetings of MERCK KGaA (Darmstadt). J. Liermann, E. Ben-Josef, M. Syed, K. Herfarth, and P. Naumann declare that they have no competing interests.
: The presented study is in accordance with the ethical standards of the institutional research committee (ethics committee of the University of Heidelberg, Germany, S‑688/2020) and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards.